The Effects of Short-Chain Fatty Acids in Psychosocial Stress-Induced Impairment on Core Executive Functions
NCT ID: NCT06286943
Last Updated: 2024-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
80 participants
INTERVENTIONAL
2024-07-31
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A triple-blind randomized placebo-controlled parallel group trial will be conducted to compare the effects of SCFAs vs. placebo on core EFs (working memory \[WM\], cognitive flexibility \[CF\], response inhibition \[RI\]) under stress vs. no-stress conditions, after one week of SCFA vs. placebo treatment.
First, the effects of SCFAs on stress-induced changes in core executive functions, with WM as the primary outcome, and CF and RI as secondary outcomes will be tested. Second, interindividual differences in microbiota composition (particularly abundance of SCFA-producers), saliva cortisol and serum SCFA levels will be explored to assess whether they are associated with interindividual differences in core EFs at baseline or following acute stress.
Each participant will undergo 2 study visits: one will involve a stress condition and the other will involve a no-stress condition. Each study visit is preceded by a 1-week intervention or placebo period and separated by a 3-4 week washout period. To induce stress, participants will perform the Maastricht Acute Stress Task (MAST) or sham MAST as the control condition. To assess EF performance, three cognitive tasks will be performed 15 minutes after task offset: n-back task for WM; Stop Signal Task for RI; and Wisconsin Card Sorting Test for CF. Saliva samples will be collected before, during and after the (sham) MAST to assess the cortisol response. Blood samples will be collected throughout all study visits to quantify serum SCFAs, inflammatory markers and ACTH. Additionally, cardiovascular variables will be measured, and self-report questionnaires will be completed to evaluate autonomic response to the condition and subjective stress responses, respectively
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brain Responses to Short-Chain Fatty Acid Intervention
NCT06546683
The Role of Short Chain Fatty Acids in Microbiota-gut-brain Axis
NCT03688854
Investigating the Effects of Dietary Phospholipids on Measures of Human Brain Health and Psychological Wellbeing
NCT06107075
Investigating the Effects of Dietary Phospholipids on Stress Reactivity and Recovery
NCT06109922
Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)
NCT00644423
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Microcrystalline cellulose placebo capsules.
Placebo
Microcrystaline cellulose placebo capsules.
Maastricht Acute Stress Task
The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
No-stress control task
The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
SCFAs
Colon-delivery Capsules of Short Chain Fatty Acids.
Short Chain Fatty Acids (SCFAs).
Colon-delivery capsules of SCFAs.
Maastricht Acute Stress Task
The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
No-stress control task
The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Short Chain Fatty Acids (SCFAs).
Colon-delivery capsules of SCFAs.
Placebo
Microcrystaline cellulose placebo capsules.
Maastricht Acute Stress Task
The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
No-stress control task
The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Proficiency in English and/or Dutch
* Healthy with no intestinal and/or psychological complaints
* Access to a -18°C freezer (i.e. ordinary household freezer)
* Male participants
* Age 20-40 years
* BMI 18.5-25 kg/m2
Exclusion Criteria
* Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol
* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the study
* Participation in an interventional Trial with an investigational medicinal product (IMP) or device
* Current or recent (over the past month) medication use as a (prescribed) medical treatment. This does not include isolated intakes of 'over the counter' medication (e.g. ibuprofen, paracetamol).
* Use of antibiotics within three months preceding the study.
* Current or recent (1-month) infection (e.g. common cold, influenza, COVID-19, etc.)
* Recent (1-month) vaccination (e.g. flu shot, SARS-COV-2 vaccine, etc)
* Previous or current substance/alcohol dependence or abuse (\>2 units per day or 14 units per week).
* One or more diagnoses based on the Mini International Neuropsychiatric Interview.
* One or more diagnoses based on ROME-IV for gastrointestinal disorders.
* Smoking.
* Night-shift work.
* Adherence to special diets (e.g. vegan, vegetarian, weight-loss, lactose-free, gluten-free, etc.).
* Use of pre- or probiotics within one month preceding the study.
* Previous experience with or knowledge of any of the tasks used in the study (not including questionnaires).
20 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Department of Defense
FED
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S68124
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.